FDA has accepted to review Pfizer’s (NYSE: PFE) 20-valent pneumococcal conjugate vaccine for the prevention against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, in adults ages 18 years and older. The agency will review the vaccine on a priority basis with a decision expected in June 2021.
Click here for the full Trefis coverage of Pfizer
- Should You Buy Pfizer For 25% Gains?
- All Eyes On Covid-19 Vaccine Contribution As Pfizer Reports Its Q1
- Pfizer Covid-19 Vaccine Updates: Booster Shots, E.U. Supplies
- New Developments For Covid-19 Shot Bode Well For Pfizer Stock
- Will AstraZeneca’s Covid-19 Troubles Help Pfizer Stock?
- Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?
Looking for a balanced portfolio to invest in? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
